Cargando…
Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux
INTRODUCTION: Kidney transplant recipients and patients on hemodialysis are immunocompromised populations, prioritized for COVID 19 vaccination, but excluded from vaccine trials. Data are lacking regarding humoral response to COVID vaccination in immunocompromised patients. DESCRIPTION: We investiga...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435332/ http://dx.doi.org/10.1016/j.nephro.2021.07.137 |
_version_ | 1783751771130167296 |
---|---|
author | Touré, F. Danthu, C. Hantz, S. Duval, M. El Ouafi, Z. Allot, V. Bocquentin, F. Rerolle, J.P. Alain, S. |
author_facet | Touré, F. Danthu, C. Hantz, S. Duval, M. El Ouafi, Z. Allot, V. Bocquentin, F. Rerolle, J.P. Alain, S. |
author_sort | Touré, F. |
collection | PubMed |
description | INTRODUCTION: Kidney transplant recipients and patients on hemodialysis are immunocompromised populations, prioritized for COVID 19 vaccination, but excluded from vaccine trials. Data are lacking regarding humoral response to COVID vaccination in immunocompromised patients. DESCRIPTION: We investigated early serological response after COVID 19 vaccination with Pfizer/BioNTech (BNT162b2) mRNA vaccine in groups of patients undergoing hemodialysis (n = 78), kidney transplant recipients (n = 74), and in healthy controls. Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. METHODS: Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. RESULTS: A total of 74 transplant recipients (mean age 64.8 ± 11.5 years, 38.9% women), 78 hemodialysis patients (mean age 73.5 ± 12.8 years, 40.2% women) and 7 healthy controls (mean age 51.6 ± 6.8, 42% women) were included. In controls, antibodies were detected at a significant level (> 13 AU/ml) at day 14 post-injection, and increased progressively, to peak at day 36 (median 1372 AU/mL [IQR 490.2-4540.5]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (median 4.0 AU/mL [IQR: 1.85-12.2] at day 14; 6.6 AU/mL [IQR 2.1-19.0] at day 36; 276 AU/mL [IQR 83.4-526.0] at day 58). A significant antibody level was detected in only 3 kidney transplant recipients at day 36. In hemodialysis patients, age, serum albumin and Kt/V were positively correlated with serological response (P < 0.043 and P < 0.019 respectively); non responders to HBV vaccine had the lowest titers of anti-SARS-CovV-2 antibodies (Fig. 1). CONCLUSION: Our results suggest that the post-vaccine humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, while it is lowered by the uremic condition in patients undergoing hemodialysis. |
format | Online Article Text |
id | pubmed-8435332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Masson SAS |
record_format | MEDLINE/PubMed |
spelling | pubmed-84353322021-09-13 Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux Touré, F. Danthu, C. Hantz, S. Duval, M. El Ouafi, Z. Allot, V. Bocquentin, F. Rerolle, J.P. Alain, S. Nephrol Ther Pc-04 INTRODUCTION: Kidney transplant recipients and patients on hemodialysis are immunocompromised populations, prioritized for COVID 19 vaccination, but excluded from vaccine trials. Data are lacking regarding humoral response to COVID vaccination in immunocompromised patients. DESCRIPTION: We investigated early serological response after COVID 19 vaccination with Pfizer/BioNTech (BNT162b2) mRNA vaccine in groups of patients undergoing hemodialysis (n = 78), kidney transplant recipients (n = 74), and in healthy controls. Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. METHODS: Antibody titers against SARS-CoV-2 at days 0, 14, 28, 36 and 58 after the first injection were measured. RESULTS: A total of 74 transplant recipients (mean age 64.8 ± 11.5 years, 38.9% women), 78 hemodialysis patients (mean age 73.5 ± 12.8 years, 40.2% women) and 7 healthy controls (mean age 51.6 ± 6.8, 42% women) were included. In controls, antibodies were detected at a significant level (> 13 AU/ml) at day 14 post-injection, and increased progressively, to peak at day 36 (median 1372 AU/mL [IQR 490.2-4540.5]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (median 4.0 AU/mL [IQR: 1.85-12.2] at day 14; 6.6 AU/mL [IQR 2.1-19.0] at day 36; 276 AU/mL [IQR 83.4-526.0] at day 58). A significant antibody level was detected in only 3 kidney transplant recipients at day 36. In hemodialysis patients, age, serum albumin and Kt/V were positively correlated with serological response (P < 0.043 and P < 0.019 respectively); non responders to HBV vaccine had the lowest titers of anti-SARS-CovV-2 antibodies (Fig. 1). CONCLUSION: Our results suggest that the post-vaccine humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, while it is lowered by the uremic condition in patients undergoing hemodialysis. Published by Elsevier Masson SAS 2021-09 2021-09-12 /pmc/articles/PMC8435332/ http://dx.doi.org/10.1016/j.nephro.2021.07.137 Text en Copyright © 2021 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Pc-04 Touré, F. Danthu, C. Hantz, S. Duval, M. El Ouafi, Z. Allot, V. Bocquentin, F. Rerolle, J.P. Alain, S. Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux |
title | Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux |
title_full | Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux |
title_fullStr | Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux |
title_full_unstemmed | Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux |
title_short | Cinétique de la réponse humorale après administration d’un vaccin SARS-COV-2 mRNA dans une cohorte de patients transplantés et greffés rénaux |
title_sort | cinétique de la réponse humorale après administration d’un vaccin sars-cov-2 mrna dans une cohorte de patients transplantés et greffés rénaux |
topic | Pc-04 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435332/ http://dx.doi.org/10.1016/j.nephro.2021.07.137 |
work_keys_str_mv | AT touref cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT danthuc cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT hantzs cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT duvalm cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT elouafiz cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT allotv cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT bocquentinf cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT rerollejp cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux AT alains cinetiquedelareponsehumoraleapresadministrationdunvaccinsarscov2mrnadansunecohortedepatientstransplantesetgreffesrenaux |